• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

切除5型腺病毒纤维与柯萨奇病毒和腺病毒受体(CAR)的结合并插入SIGYPLP肽的HI环,可产生一种内皮细胞选择性腺病毒。

Ablating adenovirus type 5 fiber-CAR binding and HI loop insertion of the SIGYPLP peptide generate an endothelial cell-selective adenovirus.

作者信息

Nicklin S A, Von Seggern D J, Work L M, Pek D C, Dominiczak A F, Nemerow G R, Baker A H

机构信息

Department of Medicine and Therapeutics, University of Glasgow, Glasgow G11 6NT, UK.

出版信息

Mol Ther. 2001 Dec;4(6):534-42. doi: 10.1006/mthe.2001.0489.

DOI:10.1006/mthe.2001.0489
PMID:11735337
Abstract

Adenovirus type 5 (Ad) based vectors transduce vascular endothelial cells (EC) and have been widely used for vascular gene transfer. However, many cell types express the Ad receptor (cox-sackievirus adenovirus receptor; CAR), preventing selective EC infection and precluding clinical use. We previously isolated the human EC-binding peptides SIGYPLP and LSNFHSS by phage display and demonstrated by means of a bispecific antibody that SIGYPLP directs efficient, high-level, EC-selective Ad-mediated gene transfer. We now generate genetically modified Ad fiber proteins with selective EC tropism by engineering these peptides into the HI loop of the Ad fiber. SIGYPLP, but not LSNFHSS, enhanced EC selectivity, demonstrating maintenance of peptide-cell binding fidelity upon incorporation into virions. Combining fiber mutations that block CAR binding (detargeting) with SIGYPLP insertion (retargeting) generated a novel Ad vector, AdKO1SIG, in a single component system. AdKO1SIG demonstrated efficient and selective tropism for EC compared with control Ad vectors. This is the first demonstration of genetic incorporation of a novel, mammalian, cell-selective ligand that retains its targeting fidelity in the Ad fiber HI loop, in combination with point mutations that abolish fiber-CAR interaction. This study demonstrates the potential for improving the cell-selectivity and safety of adenoviral vectors.

摘要

基于5型腺病毒(Ad)的载体可转导血管内皮细胞(EC),并已广泛用于血管基因转移。然而,许多细胞类型都表达腺病毒受体(柯萨奇病毒腺病毒受体;CAR),这会妨碍对内皮细胞的选择性感染,从而无法用于临床。我们之前通过噬菌体展示分离出了人内皮细胞结合肽SIGYPLP和LSNFHSS,并通过双特异性抗体证明SIGYPLP可介导高效、高水平的、内皮细胞选择性的腺病毒介导的基因转移。现在,我们通过将这些肽工程化到腺病毒纤维的HI环中,生成了具有选择性内皮细胞嗜性的基因改造腺病毒纤维蛋白。SIGYPLP增强了内皮细胞选择性,而LSNFHSS则没有,这表明肽与细胞结合的保真度在整合到病毒粒子后得以维持。将阻断CAR结合的纤维突变(脱靶)与插入SIGYPLP(重定向)相结合,在单一组件系统中产生了一种新型腺病毒载体AdKO1SIG。与对照腺病毒载体相比,AdKO1SIG对内皮细胞表现出高效且选择性的嗜性。这首次证明了一种新型哺乳动物细胞选择性配体在腺病毒纤维HI环中进行基因整合时能保留其靶向保真度,并结合了消除纤维与CAR相互作用的点突变。这项研究证明了改善腺病毒载体细胞选择性和安全性的潜力。

相似文献

1
Ablating adenovirus type 5 fiber-CAR binding and HI loop insertion of the SIGYPLP peptide generate an endothelial cell-selective adenovirus.切除5型腺病毒纤维与柯萨奇病毒和腺病毒受体(CAR)的结合并插入SIGYPLP肽的HI环,可产生一种内皮细胞选择性腺病毒。
Mol Ther. 2001 Dec;4(6):534-42. doi: 10.1006/mthe.2001.0489.
2
Fiber-modified adenovirus vectors containing the TAT peptide derived from HIV-1 in the fiber knob have efficient gene transfer activity.在纤维钮中含有源自HIV-1的TAT肽的纤维修饰腺病毒载体具有高效的基因转移活性。
Gene Ther. 2007 Aug;14(15):1160-5. doi: 10.1038/sj.gt.3302969. Epub 2007 May 17.
3
A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob.一种用于构建重组腺病毒载体的简化系统,该载体在其纤维钮的HI环中含有异源肽。
Gene Ther. 2001 May;8(9):730-5. doi: 10.1038/sj.gt.3301453.
4
Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells.高效且选择性地将腺相关病毒2介导的基因转移至人血管内皮细胞。
Mol Ther. 2001 Sep;4(3):174-81. doi: 10.1006/mthe.2001.0424.
5
Dual targeting of gene delivery by genetic modification of adenovirus serotype 5 fibers and cell-selective transcriptional control.通过对5型腺病毒纤维进行基因改造和细胞选择性转录控制实现基因递送的双重靶向
Gene Ther. 2004 Aug;11(16):1296-300. doi: 10.1038/sj.gt.3302292.
6
Adenovirus targeting to c-erbB-2 oncoprotein by single-chain antibody fused to trimeric form of adenovirus receptor ectodomain.通过与腺病毒受体胞外域三聚体形式融合的单链抗体靶向c-erbB-2癌蛋白的腺病毒。
Cancer Res. 2002 Jan 15;62(2):609-16.
7
The alphavbeta5 integrin of hematopoietic and nonhematopoietic cells is a transduction receptor of RGD-4C fiber-modified adenoviruses.造血细胞和非造血细胞的αvβ5整合素是RGD-4C纤维修饰腺病毒的转导受体。
Gene Ther. 2003 Sep;10(19):1643-53. doi: 10.1038/sj.gt.3302058.
8
Fiber shaft extension in combination with HI loop ligands augments infectivity for CAR-negative tumor targets but does not enhance hepatotropism in vivo.纤维轴延伸与HI环配体相结合可增强对CAR阴性肿瘤靶点的感染性,但不会增强体内嗜肝性。
Gene Ther. 2002 Aug;9(16):1101-8. doi: 10.1038/sj.gt.3301815.
9
Adenovirus vectors with chimeric type 5 and 35 fiber proteins exhibit enhanced transfection of human pancreatic cancer cells.具有5型和35型嵌合纤维蛋白的腺病毒载体对人胰腺癌细胞的转染能力增强。
Int J Oncol. 2008 Dec;33(6):1141-7.
10
A fiber modified adenovirus vector that targets to the EphrinA2 receptor reveals enhanced gene transfer to ex vivo pancreatic cancer.一种靶向 EphrinA2 受体的纤维修饰腺病毒载体可增强离体胰腺癌的基因转移。
Int J Oncol. 2010 Jan;36(1):233-44.

引用本文的文献

1
-targeted gene delivery using adenovirus-antibody site-specific covalent conjugates.使用腺病毒-抗体位点特异性共价缀合物进行靶向基因递送。
Mol Ther Methods Clin Dev. 2025 May 26;33(2):101497. doi: 10.1016/j.omtm.2025.101497. eCollection 2025 Jun 12.
2
Next-Generation Adenoviral Vector-Based Vaccines for Severe Acute Respiratory Syndrome Coronavirus-2.基于下一代腺病毒载体的严重急性呼吸综合征冠状病毒2疫苗
Vaccines (Basel). 2025 Apr 14;13(4):406. doi: 10.3390/vaccines13040406.
3
The Adenovirus Vector Platform: Novel Insights into Rational Vector Design and Lessons Learned from the COVID-19 Vaccine.
腺病毒载体平台:对合理载体设计的新见解和从 COVID-19 疫苗中吸取的经验教训。
Viruses. 2023 Jan 11;15(1):204. doi: 10.3390/v15010204.
4
Adenoviral vectors for cardiovascular gene therapy applications: a clinical and industry perspective.腺病毒载体在心血管基因治疗中的应用:临床和产业视角。
J Mol Med (Berl). 2022 Jun;100(6):875-901. doi: 10.1007/s00109-022-02208-0. Epub 2022 May 24.
5
Development of a low-seroprevalence, αvβ6 integrin-selective virotherapy based on human adenovirus type 10.基于10型人腺病毒的低血清阳性率、αvβ6整合素选择性病毒疗法的开发。
Mol Ther Oncolytics. 2022 Mar 16;25:43-56. doi: 10.1016/j.omto.2022.03.007. eCollection 2022 Jun 16.
6
Vascular Endothelial Cells: Heterogeneity and Targeting Approaches.血管内皮细胞:异质性与靶向策略。
Cells. 2021 Oct 10;10(10):2712. doi: 10.3390/cells10102712.
7
Nonreplicating Adenoviral Vectors: Improving Tropism and Delivery of Cancer Gene Therapy.非复制型腺病毒载体:改善癌症基因治疗的靶向性与递送
Cancers (Basel). 2021 Apr 14;13(8):1863. doi: 10.3390/cancers13081863.
8
Hitting the Target but Missing the Point: Recent Progress towards Adenovirus-Based Precision Virotherapies.击中目标却未抓住重点:基于腺病毒的精准病毒疗法的最新进展
Cancers (Basel). 2020 Nov 11;12(11):3327. doi: 10.3390/cancers12113327.
9
Identification of folate receptor α (FRα) binding oligopeptides and their evaluation for targeted virotherapy applications.鉴定叶酸受体α(FRα)结合寡肽及其在靶向病毒治疗中的应用评估。
Cancer Gene Ther. 2020 Nov;27(10-11):785-798. doi: 10.1038/s41417-019-0156-0. Epub 2020 Jan 6.
10
Cardiac Targeting Peptide, a Novel Cardiac Vector: Studies in Bio-Distribution, Imaging Application, and Mechanism of Transduction.心脏靶向肽,一种新型心脏载体:在生物分布、成像应用和转导机制方面的研究。
Biomolecules. 2018 Nov 14;8(4):147. doi: 10.3390/biom8040147.